Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Update

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 6,060,000 shares, an increase of 7.3% from the March 15th total of 5,650,000 shares. Approximately 12.3% of the company’s stock are sold short. Based on an average daily trading volume, of 540,200 shares, the short-interest ratio is currently 11.2 days.

Deciphera Pharmaceuticals Stock Performance

DCPH traded down $0.12 on Wednesday, hitting $14.72. The company had a trading volume of 304,313 shares, compared to its average volume of 520,367. The stock has a fifty day moving average price of $15.68 and a 200-day moving average price of $14.19. Deciphera Pharmaceuticals has a 12-month low of $9.90 and a 12-month high of $17.73. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -6.43 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, February 6th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The firm had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. During the same quarter in the previous year, the company posted ($0.60) earnings per share. The company’s revenue was up 32.9% compared to the same quarter last year. Analysts forecast that Deciphera Pharmaceuticals will post -2.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on DCPH shares. JPMorgan Chase & Co. upped their price target on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 20th. Stifel Nicolaus upped their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Deciphera Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DCPH. China Universal Asset Management Co. Ltd. increased its stake in shares of Deciphera Pharmaceuticals by 96.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares during the last quarter. Quest Partners LLC purchased a new position in Deciphera Pharmaceuticals during the 4th quarter valued at about $30,000. Lazard Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals in the 1st quarter valued at about $57,000. Compass Wealth Management LLC acquired a new stake in Deciphera Pharmaceuticals in the 4th quarter valued at about $70,000. Finally, Advisor Group Holdings Inc. raised its position in shares of Deciphera Pharmaceuticals by 78.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company’s stock worth $71,000 after acquiring an additional 1,898 shares in the last quarter. 70.96% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.